Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Verve Therapeutics is a clinical-stage biotech developing single-course gene editing medicines targeting liver genes to treat cardiovascular disease. Its pipeline includes therapies for lowering LDL cholesterol and Lp(a), aiming to provide durable, one-time treatments for conditions like familial hypercholesterolemia and ASCVD. Utilizing innovative gene editing, lipid nanoparticle delivery, and human genetic insights, the company seeks to transform cardiovascular care with scalable, permanent solutions.
This description was generated via AI from an annual report. Updated about 1 year ago.